JnJ seeks USFDA nod for Darzalex Faspro-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned

Raritan: Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) for whom autologous stem cell transplant (ASCT) is deferred or who are ineligible for ASCT.

This submission is supported by data from the Phase 3 CEPHEUS study (NCT03652064), which showed 60.9 percent of patients achieved minimal residual disease (MRD)-negativity with D-VRd and the risk of progression or death was reduced by 43 percent. The CEPHEUS study evaluated the efficacy and safety of D-VRd compared to bortezomib, lenalidomide and dexamethasone (VRd) for NDMM patients for whom ASCT was not planned as initial therapy (transplant ineligible or deferred).

The D-VRd regimen increased depth and durability of responses compared to VRd, including the primary endpoint of overall MRD-negativity rate (10-5) of 60.9 percent vs 39.4 percent at a median follow-up of 58.7 months (odds ratio [OR], 2.37; 95% confidence interval [CI], 1.58-3.55; P<0.0001). The sustained MRD-negativity rate favored D-VRd 48.7 percent vs 26.3 percent for VRd (P<0.0001). The study also demonstrated that D-VRd significantly reduced the risk of progression or death by 43 percent (hazard ratio, 0.57; 95% CI, 0.41-0.79; P<0.0005) vs VRd and achieved an overall complete response (CR) or better rate of 81.2 percent with D-VRd vs 61.6 percent with VRd (P<0.0001). The overall safety profile of D-VRd was consistent with the known safety profiles for DARZALEX FASPRO and VRd.

“DARZALEX FASPRO-based therapies continue to be at the forefront of multiple myeloma research. We’re encouraged that the FDA Oncologic Drugs Advisory Committee recently voted in favor of MRD-negativity as an acceptable endpoint in multiple myeloma trials. CEPHEUS is the first registrational study with a primary endpoint of MRD-negativity filed by Johnson & Johnson in multiple myeloma,” said Craig Tendler, M.D., Vice President, Late Clinical Development and Global Medical Affairs, Johnson & Johnson Innovative Medicine. “The data from CEPHEUS add to the body of evidence for DARZALEX FASPRO in newly diagnosed multiple myeloma and, together with the results of the PERSEUS study, demonstrate the potential benefit of this quadruplet regimen for newly diagnosed patients, regardless of transplant eligibility.”

Data from CEPHEUS was presented as a late-breaking oral presentation (Abstract #OA-63) at the 2024 International Multiple Myeloma Society (IMS) Annual Meeting.

Read also: Darzalex-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma

Powered by WPeMatico

Shilpa Pharma Lifesciences receives CEP from EDQM for API, Desmopressin

Karnataka: Shilpa Medicare Limited’s 100% subsidiary, Shilpa Pharma Lifesciences Limited has received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Desmopressin.

Desmopressin is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis. Desmopressin helps to reduce frequent urination and excessive thirst. This is used to treat central diabetes insipidus and bedwetting.
“We at Shilpa have always been investing in challenging chemical synthesis. With unwavering commitment and belief in our technical capabilities, we have invested in developing a versatile peptide portfolio over past few years and Desmopressin is the first peptide molecule to receive CEP from the European Regulators. This CEP showcases our proficiency in quality-oriented development as well as commercial manufacturing capabilities that meet the expectations of global quality standards paving way for more such products to follow”, said Mr. Keshav Bhutada, Executive Director- Shilpa Pharma Lifesciences Limited.

Read also: Shilpa Medicare announces submission of NDA for Oxylanthanum Carbonate to USFDA by Unicycive Therapeutics

Shilpa is an integrated pharmaceutical group with business interests in niche Oncology & Nononcology APIs, Peptides, Polymers, differentiated finished dosage formulations including orally dispersible films & transdermal patches along with carefully crafted biological portfolio. Shilpa also provides end-to-end CDMO services to global pharmaceutical companies across all its business segments based on its R&D and manufacturing capabilities backed by four R&D units and seven manufacturing facilities.

Read also: Shilpa Medicare gets USFDA nod for Bortezomib Injection for multiple myeloma

Powered by WPeMatico

NEET 2024: UP DGME gives resignation deadline to Round 1, 2 allotted Candidates

Uttar Pradesh- Through a recent notice, the Uttar Pradesh Director General of Medical Education (UPDGME) has given a deadline to all the candidates who want to resign from their admitted seats they secured in Round 1 or Round 2 counselling sessions.

In its notice, the counselling body said, “The candidates admitted through the first and second round of counseling are informed that if they then two days before the filling of the online counseling form of the third round i.e. on the date After 09.10.2024, the candidate can resign from his/her seat till 02.00 PM by appearing in person at the same Medical College/Nodal Center where the admission process has already been done by the candidate.”

Resignations will not be accepted through any other means, the notice added.

The Round 2 counselling session was over on October 3. As per the seat matrix, a total of 5381 seats were vacant across MBBS and BDS colleges of Uttar Pradesh.

CHOICE FILLING AND ALLOTMENT PROCESS FOR UP NEET COUNSELLING:

1 After depositing the security amount, the candidate will have to do choice filling.

2 Candidates will be free to select all the options from the available options for choice locking.

3 After choice filling, it will be mandatory to lock the choices. In case of not locking the choices, seat allotment will not take place.

4 The candidate will be allotted the available seats as per his/her rank from the options selected by him/her.

5 The counselling process will be conducted through an online medium in four rounds (first, second, third and stray vacancy rounds).

6 Candidates will be eligible to upgrade the seat allotted to them from the counselling of the first and second rounds to counselling of the third round.

7 If any other seat is allotted as per the option given by the candidate for re-allocation, then the previously allotted seat will automatically become vacant and will be allotted to any other eligible candidate. In case there is no reallocation, the seat occupied by the candidate earlier will remain as it is.

8 During choice filling for re-allocation, candidates should not fill the option of the seat admitted in the counselling of the previous round in the counselling of the next round. If after filling the option of the previously admitted seat, the same seat is again allotted to the candidate as a result of re-allocation, then in such a case the candidate will have to complete the admission process again. Otherwise, the previously admitted seat will be automatically cancelled. The entire responsibility for this will be of the candidate himself.

To view the official Notice, Click here :  https://medicaldialogues.in/pdf_upload/2198-1-255578.pdf

Powered by WPeMatico

CENTAC Releases BSMS, BHMS, BUMS Seat Matrix, Draft Merit List, Counselling on October 8

Puducherry- The Centralised Admission Committee (CENTAC) has recently published the schedule and Draft Merit list for BSMS, BHMS and BUMS courses on its official website. The draft Merit list is prepared based on the National Eligibility and Entrance Test-Undergraduate (NEET UG) 2024 score.

In this regard, CENTAC has published a notice informing that the objections if any, may be submitted through Grievances in the login dashboard or email on or before 07 October 2024, 11.00 am. No, objections will be allowed after the last date. After disposing of the objections, if any, the Final Merit List will be published on 07 October 2024.

Meanwhile, physical Counselling for BSMS, BHMS and BUMS courses is scheduled on Tuesday, 08 October 2024 at 11.00 a.m. at CENTAC Office, Puducherry.

Along with this, CENTAC has also released the seats available for the BSMS, BHMS and BUMS courses. As per the seats matrix, a total of 5 seats are available in the said courses for the academic year 2024. Of these, 2 seats are vacant in BSMS, 2 seats are vacant in BHMS and 1 seat is vacant in BUMS.

Also Read: CENTAC Extends Deadlines for NEET 2024 Round 2 Registration, Round 1 Seat Withdrawal, Course Preference Submission

SEATS AVAILABILITY

S.NO

COURSE

COLLEGE

NO.OF SEATS

1

BSMS

Government Siddha Medical College, Palayamkottai, TN.

2

2

BHMS

Government Homoeo Medical College, Thirumangalam, Madurai, TN.

1

3

BHMS

Government Homeo Medical College, Bangalore, Karnataka.

1

4

BUMS

Government Unani College, Chennai, TN.

1

TOTAL

5

IMPORTANT POINTS

1 Candidates should report with all original certificates including Marksheets, and Renewed Residence certificates for counselling.

2 Candidates once allotted BSMS, BHMS and BUMS course seats will not be considered for further rounds of counselling for and course in CENTAC.

CENTAC is a common admission portal for all the colleges of Puducherry and is established by the Government of Puducherry. Under this, the candidates who have passed the qualifying examination and appeared in such a qualifying examination are eligible for admission. There are various courses under its umbrella. Centralised Admission Committee (CENTAC), Government of Puducherry, conduct admissions for first-year MBBS, BAMS, BDS, BVSc & AH, BPT, BSc (Nursing), BSc (MLT), B Pharma, and postgraduate programmes, etc.

To view the notice, click the link below

https://medicaldialogues.in/pdf_upload/centac-releases-bsms-bhms-bums-seat-matrix-draft-merit-list-objections-invited-before-october-7-255533.pdf

Powered by WPeMatico

3 yrs Compulsory Rural Service, Rs 50 Lakh Penalty for PG Medical degree, Rs 25 lakh for PG Diploma: Karnataka Bond Policy

Bengaluru: MBBS or BDS graduates getting admitted to postgraduate medical/dental degree courses in Karnataka Government medical institutes must undergo three years of compulsory rural service or pay Rs 50 lakh as a penalty. Besides, the bond service penalty is Rs 25 lakh for the candidates getting admitted to PG medical/dental diploma courses. 

The Karnataka Examinations Authority (KEA) shared the information in this regard on its official website. At the time of admission to PG Medical/Dental Degree/Diploma courses, the candidates are required to submit compulsory rural service bond on Rs 100 stamp paper and undertaking for three years of service on Rs 200/- stamp paper duly notarized at the time of admission.

In the undertaking as required under Rule 15(6) of the Karnataka Conduct of Entrance Test for Selection and Admission to the Post-Graduate Medical and Dental Degree and Diploma Courses Rules, 2006, the candidates admitted under ‘All India Quota’/’State Quota’ PG medical degree/diploma courses will have to state the following:

“I am aware of the fact that the tuition fee for Government seat is highly subsidized, I shall be under an obligation to serve the State of Karnataka for a minimum period of three years after completion of my post-graduate course as required under rule 15(6) of the Karnataka conduct of entrance test for selection and admission to the post-graduate medical and dental degree and diploma course rules, 2006. After reading and fully understanding the abovementioned Rules, I have opted for the “Government’ seat”,” states the undertaking.

“In compliance with the above Rule 15(6), I hereby furnish the undertaking voluntarily, with my free will that I shall abide by the condition to serve the Government of Karnataka for a period of three years after completion of my post-graduate course in any location decided by the Government of Karnataka, and that If I fail to comply with undertaking, myself and/or my sureties mentioned below do hereby bind ourselves and each of us, our and each of heirs, executors and administrators jointly and severally to pay to the Governor of Karnataka on demand, we shall pay a penalty of Rs. 50.00 lakh (RUPEES FIFTY LAKH ONLY) for post-graduate degree and Rs. 25.00 lakhs (RUPEES TWENTY FIVE LAKH ONLY) for post-graduate diploma to the Government and only after payment of penalty, I shall collect my original documents which are in the custody of the Institution,” it further mentions. 

Compulsory Rural Service Bond for Non-in-service Candidates for All Categories: 

Apart from the candidates getting admitted to government seats, the non-in-service candidates from all the category candidates allotted to Government or Private or Deemed Colleges under the Government quota, Private Quota, NRI Quota, or Management Quota will also have to submit Compulsory Rural Service Bond Format (executed on a stamp paper of Rs 100 and duly notarized). The candidates will have to submit this at the time of collecting admission order at KEA.

As per the undertaking, the candidate will have to state, “I understand that all the candidates (other than the candidates who have undergone compulsory rural service after award of MBBS degree) who take admission to PG Medical Degree/Diploma courses and successfully complete the Post Graduate Degree/ Diploma shall under go one-year compulsory service in Government hospital in urban area as per Karnataka Compulsory service training by the candidates completed medical courses (counseling, allotment, and certification) as per Karnataka Compulsory Service Act 2012 as amended in 22/09/2017 and rules there under to the said act.”

“I am fully aware of the fact that the candidates will be entitled to only temporary registration until completion of such service. I shall be abide voluntarily to the said condition,” the undertaking further mentions.

To view the document, click on the link below:

https://medicaldialogues.in/pdf_upload/kea-bond-255589.pdf

Also Read: 1-year Compulsory Bond Service, Rs 15 Lakh Penalty: Karnataka Bond policy for MBBS admissions

Powered by WPeMatico

Health Bulletin 05/ October/ 2024

Here are the top health news for the day:

Court dismisses Rs 1 crore medical negligence claim, rules MBBS intern not a hospital employee

While observing that an MBBS intern cannot be considered a regular employee at the hospital, the National Consumer Disputes Redressal Commission (NCDRC) recently dismissed a compensation claim of Rs 1 crore by a deceased student’s father.

Filing the plea, the complainant had alleged that his 24-year-old son, who was undergoing his mandatory internship at Amravati Medical College and Hospital, had died due to medical negligence.
For more details, click the link below
NMC seeks report from Rajasthan Government on fake doctor registrations

Taking cognizance of the alleged fake doctors’ registration scam at the Rajasthan Medical Council (RMC), the National Medical Commission (NMC) has sought a report from the State Health Department, the Times of India has reported.

Confirming this, the Principal Secretary of the Health Department, Gayatri Rathore informed TOI that “A five-member committee is working on it. They are collecting data and factual details in the case. NMC has demanded complete details in the case, and we will share those with them once the final report is prepared.”
For more details, click the link below
NMC sets deadline for medical colleges offering PG courses to submit annual declaration report

The National Medical Commission (NMC) has asked all the medical colleges/institutes running postgraduate medical courses to submit an Annual Disclosure Report in respect of each PG medical course run by them.

This two-part Annual Disclosure Report consists of Standard Assessment Form Part-A, which is Institutional Information Common for all PG Specialties, and Standard Assessment Form Part-B for Broad/Super Specialty courses.

For more details, click the link below

Powered by WPeMatico

Health Ministry approval to 8 new medical colleges in Maharashtra, 800 MBBS seats to be added

Mumbai: In a major boost to medical education in Maharashtra, the Union Ministry of Health and Family Welfare has granted permission to set up 8 new government medical colleges in the state with 100 MBBS seats each for the academic year 2024-25.

These eight new government medical colleges will be established in Ambernath, Gadchiroli, Amravati, Washim, Jalna, Buldhana, Hingoli, and Bhandara districts. 

With the increase in 8 new medical colleges, the state will gain a total of 800 MBBS seats. Although the state government and the central government have given their approval, these medical colleges are still awaiting approval from the National Medical Commission (NMC). 

Previously the National Medical Commission (NMC) gave its approval for two more new medical colleges in the State for 50 MBBS seats each in Mumbai and Nashik.

Also read- Maharashtra Govt Approves 2 New Medical Colleges with 100 MBBS Seats Each

Issuing eight separate orders in this regard, the central government directed the NMC to issue a Letter of Permission (LoPs) to GMCs in these eight districts for the formation of the medical colleges, reports Indian Express

This comes after the central government issued new approvals following the second appeal submitted by the state’s Medical Education department in September. The orders, dated September 30, state that after reviewing the appellant’s documents and submissions, the Central Government has directed the National Medical Commission (NMC) to issue Letters of Permission (LoPs).

The Maharashtra government earlier this year applied to establish 10 new Government Medical Colleges (GMCs) across various districts, each with a capacity of 100 seats. However, in August, only two of these applications were approved, accounting for a total of 100 seats, while the remaining eight applications were denied. The Medical Assessment and Rating Board (MARB) had identified several deficiencies in these colleges during inspections, citing failure to meet the minimum standards required by the NMC.

Also Read:Only 2 out of 12 new medical colleges get NMC nod in Maharashtra

In response, the state’s Medical Education department filed an appeal against this decision. The latest orders from the Government of India indicate that the colleges have since provided additional documents and justifications, showing compliance with the necessary standards outlined by the NMC.

“The committee further opines that if the NMC carries out inspections of the college at any stage and finds that the college is deficient in availability of faculty infrastructure etc. the permission for starting the college may be withdrawn by NMC,” adds the order.

With the state government aiming to establish a medical college in every district, there are now a total of 35 government medical colleges in Maharashtra. A total of 4,850 students will get admission from this government medical college every year.

The move comes in line with the state government’s policy of establishing at least one medical college in every district. This will help so many aspirants pursue medical education within the state when a number of aspirants are leaving for abroad due to the lack of MBBS seats in Maharashtra. 

Each new college will receive Rs 403 crore in funding to support infrastructure development. 

Powered by WPeMatico

WHO approves first mpox diagnostic test for emergency use, boosting global access

The World Health Organization (WHO) has listed the first mpox in vitro diagnostic (IVD) under its Emergency Use Listing (EUL) procedure, an important step in improving global access to mpox testing. The approval for emergency use of the Alinity m MPXV assay, manufactured by Abbott Molecular Inc., will be pivotal in expanding diagnostic capacity in countries facing mpox outbreaks, where the need for quick and accurate testing has risen sharply. Early diagnosis of mpox enables timely treatment and care, and control of the virus.

Limited testing capacity and delays in confirming mpox cases persist in Africa, contributing to the continued spread of the virus. In 2024, over 30 000 suspected cases have been reported across the region, with the highest numbers in the Democratic Republic of the Congo, Burundi, and Nigeria. In the Democratic Republic of the Congo, only 37% of suspected cases have been tested this year.

The presence of the monkeypox virus is confirmed by nucleic acid amplification testing (NAAT), such as real-time or conventional polymerase chain reaction (PCR), as stated in the WHO Interim Guidance on Diagnostic testing for the monkeypox virus (MPXV). And the recommended specimen type for diagnostic confirmation of monkeypox virus (MPXV) infection in suspected cases is lesion material.

The Alinity m MPXV assay is a real-time PCR test that enables detection of monkeypox virus (clade I/II) DNA from human skin lesion swabs. It is specifically designed for use by trained clinical laboratory personnel who are proficient in PCR techniques and IVD procedures. By detecting DNA from pustular or vesicular rash samples, laboratory and health workers can confirm suspected mpox cases efficiently and effectively.

“This first mpox diagnostic test listed under the Emergency Use Listing procedure represents a significant milestone in expanding testing availability in affected countries,” said Dr Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products. “Increasing access to quality-assured medical products is central to our efforts in assisting countries to contain the spread of the virus and protect their people, especially in underserved regions.”

The EUL process accelerates the availability of life-saving medical products, such as vaccines, tests and treatments, in the context of a Public Health Emergency of International Concern (PHEIC). On 28 August 2024, WHO called on mpox IVDs manufacturers to submit an expression of interest for EUL, recognizing the urgent need to bolster global testing capacities as the virus continued to spread. The EUL process assesses the quality, safety, and performance of essential health products, such as diagnostic tests, to guide procurement agencies and WHO Member States in making informed decisions for time-limited emergency procurement.

So far, WHO has received three additional submissions for EUL evaluation, and discussions are ongoing with other manufacturers of mpox IVDs to ensure a wider range of quality-assured diagnostic options. This will support countries which have not approved the medical products through their own approval processes to procure the critically needed tests through UN agencies and other procurement partners.

The EUL for Alinity m MPXV assay, allowing for its use, will remain valid as long as the PHEIC, justifying the emergency use of mpox in vitro diagnostics, is in effect.

Powered by WPeMatico

AIIMS Patna Vacancies: SR Post In Various Departments, Check Out All Details Here

Patna: The All India Institute of Medical Sciences, (AIIMS Patna) has announced vacancies for the post of Senior Resident (Non-Academic) on an contract basis at various departments in this medical institute.

AIIMS, Patna an Autonomous Institute of National Importance is one of the new AIIMS and apex healthcare Institutes established by the Ministry of Health & Family Welfare, Government of India under the Pradhan Mantri Swasthya Suraksha Yojna (PMSSY).

AIIMS Patna Vacancy Details:

Total No of Vacancies: 51

The Vacancies are in the Departments of Anaesthesia, Antomy, Biochemistry, Cardiology, Community Medicine, Clinical Hematology, Dermatology, ENT, Forensic Medicine, General Medicine, Neurology, Ophthalmology, Obstetrics and Gynaecology, Pathology, Physical Medicine and Rehabilitation, Paediatrics, Psychiatry, Pharmacology, Radiology, and Radiation Oncology.

The Date of Walk-In-Interview: 7th October 2024.

Reporting Time & Venue 07:30 AM at E-classroom, Administrative Building, AIIMS Patna

Time & Venue for Walk-in Interview From 09:00 AM onwards at Committee Room, Administrative Building, AIIMS Patna

For more details about Qualifications, Age, Pay Allowance, and much more, click on the given link below:
https://medicaljob.in/jobs.php?post_type=&job_tags=AIIMS+Patna&location=&job_sector=all

Eligible Candidates Note:-

FILLING UP OF APPLICATION FORM ON THE DATE OF WALK-IN INTERVIEW:

a) For filling up of application on the date of walk-in interview, the candidates have to bring the following documents (original and one set of self-attested copies) which also needs to be produced at the time of walk-in interview:-

Recent Passport size photograph of candidate

1. face clearly visible

2. The picture should be in colour, against a light-coloured, preferably white background

3. Caps, hats and dark glasses are not acceptable. Religious headwear is allowed but it must not cover your face

4. Demand Draft in original (if applicable)

5. Aadhar Card

6. Date of Birth/SSC/HSSC pass certificate (mentioning Date of Birth)

7. MBBS Degree Certificate

8. Internship Completion Certificate

9. MD/MS/DNB/DM/M.Ch Degree/Provisional Degree Certificate

10. UG & PG NMC/State Registration Certificate

11. Category/PwBD Certificate (If seat is claimed in reserved category)

12. Experience Certificate, if any

13. NOC from present employer (applicable for those working in Govt./Pvt. organization)

14. Any other relevant documents (viz. Research Work, Publication etc.)

b) The candidates are requested to fill the correct details regarding name/age/gender/caste/address/educational qualification and other relevant fields mentioned in the application form.

c) Once form is submitted, there shall be no provision for making changes in the application form.

d) Payment of application fees by any other mode viz. Cash, Cheque, Money Orders, Postal Orders, Pay Orders, Banker’s Cheques, Postal Stamps, etc., will not be accepted. Such applications will be summarily rejected. The decision of Executive Director, AIIMS Patna in this regard shall be final and binding.

Also Read:Assistant Professor Post Vacancies At Kerala Public Service Commission: Applications Open

Powered by WPeMatico

Brownfield Medical College Policy amended! 7 New Medical Colleges to Come Up in Gujarat

Gandhinagar: Bringing good news to the medical aspirants in Gujarat, seven new medical colleges are going up be set up in the State as the Government has amended its brownfield medical college policy.

Confirming this, the State Health Minister Rushikesh Patel recently said that with the amended policy, seven new medical colleges will be started in Botad, Devbhumi Dwarka, Gir-Somnath, Kheda-Nadiad, Chhota Udepur, Mahisagar-Lunawada, and Dang-Ahwa.

The decision in this regard was taken at a cabinet meeting held at Gandhinagar under the chairmanship of Chief Minister Bhupendrabhai Patel, Desh Gujarat has reported.

The Brownfield Medical College Policy was introduced by the State Government in 2016 to start new medical colleges at the district-level government hospitals. At present, Gujarat has seven functional brownfield medical colleges including Palanpur (Banaskantha), Amreli, Dahod, Bharuch, and Tapi-Vyara.

Also Read: UP to set up New Medical Colleges- 1 each with 100 MBBS seats in Baghpat, Hathras, Kasganj

Indian Express has reported that as per the amended policy, now the hospital will have to provide free medical treatment to pregnant woman till 20 days of delivery and children up to one year. For this purpose, the hospital has to set up a neonatal intensive care unit and a unit of 10 beds for dialysis-related services.

Further, as per the amended policy, the blood bank at the hospital will have to be continued even after the formation of a medical college and the patients will have to be provided blood as per the requirement free of cost.

The State Government will not provide any financial assistance under the new policy to the person or institute to expand the hospital in order to fulfill the requirement of a minimum of 300 beds. The hospital will have to implement all the schemes of the State and the Central Governments without getting any schematic funds.

However, the hospital shall be entitled to retain the income under the PMJAY scheme. Twenty-five percent of the gross amount of the income generated from the diagnosis fee for the treatment provided to the patients in that hospital and the PMJAY fee shall be deposited in the patient welfare committee, Desh Gujarat has reported.

Further, the hospital will have Rogi Kalyan Samiti and the institute will have to strictly implement the Gujarat Clinical Establishment (Registration and Regulation) Act, 2021 and its rules, as amended from time to time, promulgated by the State Government.

Desh Gujarat has reported that all treatments except heart, brain, cancer and organ transplant, cochlear implant shall be given free of cost in case of students referred under the school health programme. Further, the blood bank at the hospital shall be continued compulsorily even after Brown Field Medical College is established. Free blood shall be provided to all as per requirement considering the need patient’s need and priority to the nearby government institutes as per requirement without any discrimination.

After the organization take over the management of the hospital, trauma patients and vehicle accident patients will have to be compulsorily given free treatment.

Earlier this year, the former Union Health Minister Mansukh Mandaviya had shared the details regarding the availability of medical seats. As per the data, Gujarat has altogether 40 medical colleges with an intake capacity of 7150 MBBS and 2010 PG medical seats. Among these, 23 Governmenty medical colleges have 4250 MBBS seats. Further, the State also has 17 private medical colleges with an intake capacity of 2900 MBBS seats.

Also Read: 3 New Private Medical Colleges to Come Up in Gujarat, 400 MBBS seats to be added

Powered by WPeMatico